Antiangiogenic treatment as a pre-operative management of alveolar soft-part sarcoma.

Authors :: Conde N
Cruz O
Albert A
Mora J
Source :: Pediatric blood & cancer [Pediatr Blood Cancer] 2011 Dec 01; Vol. 57 (6), pp. 1071-3. Date of Electronic Publication: 2011 Jul 09.
Publication Year :: 2011
Abstract: Alveolar soft-part sarcoma (ASPS) is a rare tumor. Cure is based solely on radical surgery. The general prognosis is poor. The tongue is an unusual site in adults, but not in children. Tumor removal can cause a severe impact on quality of life, even if reconstruction is possible. ASPS is a highly vascularized tumor and antiangiogenic therapy may have a role. We describe the use of the antiangiogenic combination bevacizumab and celecoxib in the preoperative management of a patient with an ASPS of the tongue.<br /> (Copyright © 2011 Wiley-Liss, Inc.)

Subjects :: Antibodies, Monoclonal, Humanized therapeutic use
Bevacizumab
Celecoxib
Child, Preschool
Female
Humans
Neovascularization, Pathologic diagnosis
Pyrazoles therapeutic use
Quality of Life
Sarcoma, Alveolar Soft Part diagnosis
Sarcoma, Alveolar Soft Part surgery
Sulfonamides therapeutic use
Tongue Neoplasms diagnosis
Tongue Neoplasms surgery
Treatment Outcome
Angiogenesis Inhibitors therapeutic use
Neovascularization, Pathologic drug therapy
Sarcoma, Alveolar Soft Part drug therapy
Tongue Neoplasms drug therapy

Full Text Access

Tools